DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript

Daniel Tassé: Covered a lot today and thanks for those questions. So, to recap we’re continuing to advance VITESSE, our Phase 3 study in peanut allergy children four to seven. In parallel the successful completion of the supplemental COMFORT safety studies are important. And as I shared with our colleagues asking questions here, we have two BLAs are distinct in parallel and thus one is not relating to the other one at the moment we have sign off on the protocol in toddlers, we will initiate that study as well lined up. We are very confident or remain very confident this work will support BLAs in both age groups and as we’ve picked up from dialogues with allergists at quite a AAAAI, we will pick-up when it comes to talking to investigators, we will pick-up in our market research, families want treatment options — the more treatment options are available, the more dynamic of the market will be and we all benefit from that.

And this concludes the call for today. Again, we hope that we will keep on conveying the success of our programs to 2023 and 2024. We’re laser-focused on execution. And lastly, I want to apologize again profusely for a call that started later than expected. I thank you all. Wish you a good evening.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.